PeptiDream Inc. (4587.T)
JPY 1815.0
(0.83%)
JPY 1815.0
(0.83%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 67.12 Billion JPY | 5.11% |
| 2022 | 63.86 Billion JPY | 139.92% |
| 2021 | 26.61 Billion JPY | 1.34% |
| 2020 | 26.26 Billion JPY | 47.42% |
| 2019 | 17.81 Billion JPY | -11.09% |
| 2018 | 20.04 Billion JPY | 21.44% |
| 2017 | 16.5 Billion JPY | 21.09% |
| 2016 | 13.62 Billion JPY | 13.98% |
| 2015 | 11.95 Billion JPY | 54.51% |
| 2014 | 7.73 Billion JPY | 28.99% |
| 2013 | 5.99 Billion JPY | 1.23% |
| 2012 | 5.92 Billion JPY | 1360.11% |
| 2011 | 405.86 Million JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 95.88 Billion JPY | 37.69% |
| 2024 Q1 | 69.63 Billion JPY | 3.74% |
| 2023 Q2 | 57.7 Billion JPY | -3.47% |
| 2023 Q3 | 66.1 Billion JPY | 14.56% |
| 2023 FY | 67.12 Billion JPY | 5.11% |
| 2023 Q4 | 67.12 Billion JPY | 1.55% |
| 2023 Q1 | 59.77 Billion JPY | -6.4% |
| 2022 Q4 | 63.86 Billion JPY | 24.6% |
| 2022 FY | 63.86 Billion JPY | 139.92% |
| 2022 Q3 | 51.25 Billion JPY | -1.23% |
| 2022 Q2 | 51.89 Billion JPY | -0.4% |
| 2022 Q1 | 52.1 Billion JPY | 95.74% |
| 2021 Q1 | 24.15 Billion JPY | -8.04% |
| 2021 Q4 | 26.61 Billion JPY | -4.58% |
| 2021 Q3 | 27.89 Billion JPY | 14.97% |
| 2021 FY | 26.61 Billion JPY | 1.34% |
| 2021 Q2 | 24.26 Billion JPY | 0.46% |
| 2020 Q3 | 19.02 Billion JPY | -3.73% |
| 2020 Q4 | 26.26 Billion JPY | 38.05% |
| 2020 FY | 26.26 Billion JPY | 47.42% |
| 2020 Q2 | 19.76 Billion JPY | 10.62% |
| 2020 Q1 | 17.86 Billion JPY | 0.0% |
| 2019 FY | 17.81 Billion JPY | -11.09% |
| 2019 Q3 | 18.68 Billion JPY | -6.77% |
| 2019 Q2 | 20.04 Billion JPY | 20.8% |
| 2019 Q1 | 16.59 Billion JPY | 2.23% |
| 2018 FY | 20.04 Billion JPY | 21.44% |
| 2018 Q4 | 16.22 Billion JPY | 2.56% |
| 2018 Q3 | 15.82 Billion JPY | -4.11% |
| 2018 Q2 | 16.5 Billion JPY | 34.87% |
| 2018 Q1 | 12.23 Billion JPY | -1.19% |
| 2017 Q3 | 12.52 Billion JPY | -8.13% |
| 2017 Q1 | 11.04 Billion JPY | -1.31% |
| 2017 FY | 16.5 Billion JPY | 21.09% |
| 2017 Q2 | 13.62 Billion JPY | 23.37% |
| 2017 Q4 | 12.38 Billion JPY | -1.09% |
| 2016 Q3 | 11.6 Billion JPY | -2.91% |
| 2016 FY | 13.62 Billion JPY | 13.98% |
| 2016 Q1 | 10.2 Billion JPY | 35.31% |
| 2016 Q2 | 11.95 Billion JPY | 17.16% |
| 2016 Q4 | 11.19 Billion JPY | -3.57% |
| 2015 Q2 | 7.73 Billion JPY | 28.46% |
| 2015 FY | 11.95 Billion JPY | 54.51% |
| 2015 Q4 | 7.54 Billion JPY | 6.02% |
| 2015 Q3 | 7.11 Billion JPY | -8.08% |
| 2015 Q1 | 6.02 Billion JPY | -0.33% |
| 2014 Q3 | 5.97 Billion JPY | -0.48% |
| 2014 FY | 7.73 Billion JPY | 28.99% |
| 2014 Q1 | 5.95 Billion JPY | -0.75% |
| 2014 Q4 | 6.04 Billion JPY | 1.23% |
| 2014 Q2 | 5.99 Billion JPY | 0.66% |
| 2013 Q4 | 6 Billion JPY | 3.11% |
| 2013 Q3 | 5.82 Billion JPY | -1.72% |
| 2013 Q2 | 5.92 Billion JPY | 0.0% |
| 2013 FY | 5.99 Billion JPY | 1.23% |
| 2012 FY | 5.92 Billion JPY | 1360.11% |
| 2011 FY | 405.86 Million JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | -918.721% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -5441.139% |
| GNI Group Ltd. | 62.39 Billion JPY | -7.585% |
| Linical Co., Ltd. | 18.53 Billion JPY | -262.066% |
| Trans Genic Inc. | 9.81 Billion JPY | -584.199% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | -1091.428% |
| Soiken Holdings Inc. | 6.94 Billion JPY | -866.391% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | -1054.108% |
| AnGes, Inc. | 28.89 Billion JPY | -132.333% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -7639.967% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 57.298% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -4047.259% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | -1223.666% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | -1443.183% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -2659.178% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -2728.331% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | -868.602% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -3732.632% |
| Kidswell Bio Corporation | 5.08 Billion JPY | -1219.952% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -3189.565% |
| Ribomic Inc. | 3.54 Billion JPY | -1792.358% |
| SanBio Company Limited | 5.04 Billion JPY | -1229.957% |
| Healios K.K. | 15.15 Billion JPY | -342.935% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -5356.323% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -2125.689% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -4453.578% |
| StemRIM | 9.08 Billion JPY | -639.282% |
| CellSource Co., Ltd. | 6.87 Billion JPY | -875.718% |
| FunPep Company Limited | 2.49 Billion JPY | -2594.628% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -2463.405% |
| Stella Pharma Corporation | 3.82 Billion JPY | -1656.96% |
| TMS Co., Ltd. | 3.55 Billion JPY | -1788.367% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | -1061.575% |
| Cuorips Inc. | 6.18 Billion JPY | -985.362% |
| K Pharma,Inc. | 3.31 Billion JPY | -1925.612% |
| Takara Bio Inc. | 123.2 Billion JPY | 45.517% |
| ReproCELL Incorporated | 9.05 Billion JPY | -641.517% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -2372.15% |
| StemCell Institute Inc. | 6.54 Billion JPY | -925.921% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | -860.495% |
| CellSeed Inc. | 2.46 Billion JPY | -2622.348% |